Authorised representative (AR)

Galderma Hong Kong Limited

高德美大药厂(香港)有限公司

Hong Kong MDACS·21 represented devices·2 applicants·Feb 25, 2011 – Sep 02, 2024

Total devices

Applicants

2011

First representation

2024

Most recent

AR overview

Bilingual authorised representative information and contact details

Authorised representative (EN): Galderma Hong Kong Limited
Authorised representative (ZH): 高德美大药厂(香港)有限公司
Phone: 28240333

Timeline

First representation: Feb 25, 2011
Most recent: Sep 02, 2024

Risk class distribution

Applicant partnerships

Top manufacturers represented by this AR

Q-Med AB

Thiebaud S.A.S.

Recent registrations

Latest 15 MDACS listings represented by Galderma Hong Kong Limited

Device	Risk class	Applicant	Registered
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Sep 02, 2024
Tissue Reconstructive Materials 组织重建材料	IV	Q-Med AB Q-Med Ab	Sep 02, 2024
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Aug 16, 2024
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Aug 16, 2024
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jul 24, 2023
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jul 24, 2023
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Nov 23, 2022
Needles, Injection 针头,注射剂	II	Thiebaud S.A.S. Thiebaud S.A.S.	Jun 03, 2021
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Mar 27, 2020
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Mar 27, 2020
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jan 10, 2020
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jan 10, 2020
Needles, Injection 针头,注射剂	II	Thiebaud S.A.S. Thiebaud S.A.S.	Jul 09, 2019
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jun 04, 2019
Tissue Reconstructive Materials, Fluid 组织重建材料,液体	IV	Q-Med AB Q-Med Ab	Jan 10, 2019

About this profile

Galderma Hong Kong Limited serves as the authorised representative for 21 medical devices in Hong Kong's MDACS framework. Analyse applicant partnerships, risk class exposure, and recent regulatory activity to understand their market footprint.